Viewing nowActipio Tablet 15 mg (Pioglitazone Hydrochloride)
Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Yuhan Corporation

MFDS item code 200706313 · Approved 2007.06.01 · Insurance code 642101210
Improvement of blood glucose control in type 2 diabetes mellitus
This medication is used in conjunction with meal and exercise therapy to help control blood sugar in patients with type 2 diabetes. It can be taken alone and, in cases where blood sugar control is difficult with other oral hypoglycemic agents, it can be used in combination with sulfonylureas, metformin, or insulin. It is important for patients with type 2 diabetes to also engage in nutritional counseling, consider weight loss as needed, and maintain regular exercise. Such lifestyle improvements are significantly beneficial not only for initial treatment effects but also for sustaining the efficacy of drug therapy. This medication is used to improve blood sugar control in patients with type 2 diabetes.
This medicine is administered orally once daily, regardless of meals. Glycated hemoglobin reflects blood glucose status over the past 2 ~ 3 months. Clinically, this medicine should be administered for an appropriate period to assess changes in glycated hemoglobin (at least 3 months), unless glycemic control in the patient with diabetes deteriorates further. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this medicine is not sufficiently effective, the dose may be increased to up to 30 mg once daily. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dosage regimen. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dosage regimen. It is unlikely that the metformin dose will need to be adjusted due to symptoms of hypoglycemia during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be continued when starting combination therapy with this medicine. However, if a patient receiving this medicine with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or less, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be made individually according to glycemic control. Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Precautions, Patients with Renal Impairment).
Use is not recommended in children under 18 years of age because there is no experience with its use.
This medication may cause or worsen congestive heart failure in some patients, so symptoms and signs of heart failure should be carefully monitored at the start of treatment or after dosage increases. This medication should not be used in patients with heart failure or a history of heart failure, and if symptoms of heart failure occur, a doctor should be consulted immediately. This medication can cause fluid retention which may aggravate edema or heart failure, so healthcare personnel should be notified if symptoms of fluid retention appear. Patients with active bladder cancer or a history of bladder cancer should not take this medication, and if symptoms such as hematuria or urination difficulties occur, they should promptly inform a doctor. Patients with impaired liver function or severe kidney impairment should preferably avoid this medication and have regular liver function and kidney function tests. Women who are pregnant or may become pregnant should not take this medication, and women of childbearing potential should consider appropriate contraception while taking this medication as the risk of pregnancy may increase. Due to potential hypoglycemia, caution should be exercised for symptoms of hypoglycemia when used with insulin or other hypoglycemic agents, and dosages of other medications should be adjusted as necessary. Elderly patients or those with poor nutritional status or those engaging in vigorous exercise should use this medication cautiously, and regular monitoring for weight gain and edema is advised. During therapy, blood sugar, liver function, kidney function, and weight should be monitored regularly, and any adverse symptoms should be reported to healthcare personnel immediately. In case of an overdose, there may be no specific symptoms, but appropriate treatment should be received according to symptoms. Keep the medication out of reach of children and store it in its original container.
Congestive heart failure, excessive and rapid weight change, dyspnea, edema, fluid retention, edema, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, upper respiratory infection, urinary tract infection, back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular risk factors, worsening of congestive heart failure, emergency room visit due to congestive heart failure, progression of congestive heart failure, liver failure, diabetic macular edema with vision loss, elevated serum ALT levels, decreased hemoglobin, elevated serum creatine kinase, gross hematuria, urinary disturbances, urgency, fracture, dizziness, loss of appetite, constipation, upper abdominal pain, chest pain, fatigue, weakness, dyspepsia, nausea, dyspnea, itching, chest discomfort, tremors, chills, gastrointestinal disease, abdominal pain, epigastric discomfort, paresthesia, muscle rigidity, head discomfort, worsening of liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, abdominal pain, heart failure
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a container that prevents light and air entry, avoiding humid places. It is best to store it at room temperature between 15 and 30 degrees Celsius, especially around 25 degrees Celsius.
White or gray, round, biconvex tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Yuhan Corporation

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kyungdong Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.